Sermorelin for muscle growth has a real biological idea behind it, but not direct proof. Sermorelin can prompt the body to release more growth hormone. Small studies have found modest changes in lean mass, which means everything in the body except fat. They have not shown that sermorelin reliably adds muscle or makes healthy adults stronger. That distinction matters: a body-composition scan can move without a person lifting more weight.
How sermorelin reaches the growth-hormone pathway
Sermorelin mimics growth hormone-releasing hormone, or GHRH, a signal the brain uses to tell the pituitary gland to release growth hormone. The pituitary is a small gland at the base of the brain. The release comes in pulses rather than staying high all day.
Growth hormone can then raise insulin-like growth factor 1, or IGF-1, a hormone involved in growth and tissue repair. This explains why sermorelin is discussed in muscle-building circles. It does not prove the final result. A higher hormone reading is a step along a pathway, not the same thing as new muscle tissue or better strength.
Sermorelin also is not injected growth hormone. It sends a signal upstream and depends on the pituitary responding. Sermorelin versus HGH explains that difference in more detail.
What the small GHRH studies actually found
The most direct adult evidence is old and tiny. In a 1997 study, 11 healthy men ages 64 to 76 received GHRH 1-29, the same 29-amino-acid signal sermorelin copies, for six weeks. Nighttime growth-hormone release rose. IGF-1, body weight, body fat, and lean mass did not change. Two of six strength measures and one endurance test improved, but there was no untreated comparison group, so that result cannot establish a sermorelin effect (Vittone et al., Metabolism, 1997).
A second 1997 study followed 19 adults ages 55 to 71 using a GHRH analogue for 16 weeks after a placebo period. Growth hormone and IGF-1 rose. Lean mass increased by 2.3% in the men, not the women, while body weight and fat mass did not change (Khorram et al., Journal of Clinical Endocrinology & Metabolism, 1997). The study did not show that younger lifters would gain muscle or strength.
Those findings are a signal worth discussing with a clinician. They are not a muscle-building result that can be promised.
Lean mass is not the same as strength
The best-known broader check comes from a 2008 review of growth hormone in healthy, physically fit people. It combined 44 articles covering 27 study groups; 303 participants received growth hormone. Lean mass increased by an average of 2.1 kilograms compared with no growth hormone, but strength and exercise capacity did not improve (Liu et al., Annals of Internal Medicine, 2008).
That review studied growth hormone itself, not sermorelin, so its result cannot be handed to sermorelin as if the drugs were interchangeable. It does show why a lean-mass number needs context. Some of that change may be fluid rather than added working muscle.
CJC-1295 and ipamorelin come up in the same conversation because they also affect growth-hormone release. Their evidence does not fill the gap for sermorelin. The CJC-1295 and ipamorelin overview explains how that combination differs.
What changed in the latest evidence
As of September 6, 2026, the day this article was written, a June 18, 2026 review of performance-focused peptides reached the same practical answer. It included sermorelin and reported no current approval for a body-composition or performance use. It also noted that growth-hormone-related increases in lean mass among healthy adults can largely reflect extracellular fluid, meaning extra water held outside cells, rather than new muscle (Dominikowski et al., Frontiers in Endocrinology, 2026).
This was a review, not a new sermorelin trial. It sharpens the reason for caution; it does not close the evidence gap.
There is no sermorelin muscle-growth dose
No clinical trial has established a sermorelin dosage for muscle growth in healthy adults. The numbers repeated in forums are not a validated protocol, and a larger hormone rise is not proof of a better muscle outcome.
When sermorelin is prescribed, the provider sets the dose for the medical purpose being addressed. They may consider health history, current medicines, the prescribed formulation, baseline lab context, IGF-1 response, and side effects. The plan can change when those findings change. How sermorelin dosing decisions are made covers that clinical process without turning it into a self-directed schedule.
What a realistic muscle plan looks like
If sermorelin is part of a clinician-led plan, expectations should stay narrow. A change in IGF-1 or a body scan does not guarantee a visible change, better performance, or a new personal record. Strength training, enough food and protein, and recovery remain the parts of the plan that directly ask muscle to adapt.
It also helps to decide what result matters before treatment begins. Scale weight, lean mass on a scan, measurements, and strength are different outcomes. Treating them as interchangeable is how a modest laboratory finding turns into an oversized claim.
Where a prescription fits
There is no FDA-approved sermorelin product currently marketed—Geref was approved in 1997 and withdrawn in 2009—and the compounded formulation offered here is not FDA-approved. The withdrawal was not for safety or effectiveness reasons, according to the FDA's Federal Register notice. A licensed provider may still prescribe a compounded formulation when appropriate; that decision is between the patient and the doctor.
At Promise, a licensed U.S. provider reviews every request and decides whether a prescription is appropriate; not everyone qualifies. That review is also where a vague goal like “more muscle” gets separated into a medical question, a training question, or both.